In order to obtain accurate and meaningful data, it is essential that the analyte of interest be sufficiently stabile in the sample matrix. The stability should be proven covering the entire sample lifecycle: beginning from the time of collection until the last reported analytical result. There are many biological fluids that laboratories analyze, including plasma, serum, whole blood, urine, cerebral spinal fluid (CSF), as well as tissues such as skin, lung and brain. Each of these matrices can present stability challenges due to their varied endogenous components that can either help maintain analyte stability or be the culprit for instability. This presentation will cover some of the factors that contribute to analyte instability as well as strategies that can be used during sample collection and handling to achieve stability prior to analysis.
Corey Ohnmacht, Ph.D, Director of Science for Bioanalytical and Quality Control Laboratories, PRA Health Sciences
Corey Ohnmacht is the Director of Science for Bioanalytical and Quality Control Laboratories at PRA Health Sciences in Lenexa, Kansas (USA). Ohnmacht received his Ph.D. in chemistry from the University of Nebraska-Lincoln. He has a combined 15 years of experience at CROs with 10 years at PRA. His experience includes hands-on and oversight development of 100’s of methods with challenging analytes including proteins, peptides, nucleotides, natural products and highly unstable compounds. Ohnmacht also holds multiple publications in high-impact factor journals, co-authored a handbook on affinity chromatography as well as one for bioanalysis.Message Presenter
Who Should Attend?
- Scientists in small, mid-size and large pharmaceutical and biotech companies who develop and validate LC-MS methods for proteins in support of (pre)clinical studies
- All other industrial scientists with an interest in learning more about the possibilities of LC-MS for protein quantification
- Academic and research scientists who are interested in the technical and conceptual developments of protein LC-MS in an industrial setting
- Project managers and outsourcing/procurement staff involved in bioanalysis supporting the development of protein drugs
What You Will Learn
In this webinar, participants will learn about:
- What difficulties different biological matrices can present with respect to stability
- How the analytical technique used can determine how best to stabilize the sample
- Strategies for stabilization of samples
PRA Health Sciences
PRA Health Sciences recognizes that the world of drug development is complex and dynamic, and that’s why PRA has designed two laboratories to meet those challenges. PRA offers the highest quality services for pharmacokinetic, immunogenicity, biomarker analysis and CMC analysis, comprising a wide range of platforms for small molecules, large molecules and cell-based entities.
PRA’s Laboratories for Drug Development are managed, staffed, and supported by industry-leading experts who have the scientific knowledge and experience necessary to successfully deliver the most complex of studies.
The GLP & GMP compliant facilities in the USA and the Netherlands adhere to the latest global regulatory guidelines and expectations. PRAs technology investments and innovative service offerings are key components of goals and strategies for developing solutions for clients.
No one understands the daily pressure of tight deadlines better than the colleagues at PRA laboratories, because PRA realizes that behind every sample we analyze, a patient is waiting to be treated.